Takashi Shimada
Presidente en PHOENIXBIO CO., LTD. .
Fortuna: 110 343 $ al 31/05/2024
Cargos activos de Takashi Shimada
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
PHOENIXBIO CO., LTD. | Director/Miembro de la Junta | 01/03/2003 | - |
Presidente | 28/06/2018 | - | |
Corporate Officer/Principal | 01/03/2003 | 28/06/2018 | |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015. | Presidente | 01/06/2018 | - |
Director Ejecutivo | 01/08/2012 | 01/06/2018 | |
Presidente | 01/08/2012 | 01/06/2018 | |
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada. | Presidente | 01/12/2017 | - |
Historial de carrera de Takashi Shimada
Antiguos cargos conocidos de Takashi Shimada.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Director Administrativo | 01/01/1988 | - |
Director/Miembro de la Junta | 01/01/1988 | - |
Estadísticas
Internacional
2 | |
Japón | 2 |
Estados Unidos | 2 |
Operativa
Director/Board Member | 2 |
President | 2 |
Chairman | 2 |
Sectorial
Commercial Services | 3 |
Health Technology | 2 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas privadas | 4 |
---|---|
PhoenixBio Co., Ltd. | |
Institute of Immunology Co., Ltd.
Institute of Immunology Co., Ltd. Medical SpecialtiesHealth Technology Institute of Immunology Co., Ltd. engages in the manufacture and sale of diagnostic reagents and monoclonal antibodies for research purpose. It develops and produces Enzyme Immunoassay (EIA) kits related to infectious diseases such as hepatitis B as well as those for human hepatocellular growth factor determination. The firm also offers EIA kits for detecting hepatitis E virus antibody and for determining the genotypes of hepatitis B virus and offers immunization of 3 mice, evaluation, fusion, screening, cloning, ascites production and purification services to the research, clinical and medical industries. The company was founded by Tetsuo Nakamura on August 18, 1979 and is headquartered in Tokyo, Japan. | Health Technology |
PhoenixBio USA Corp.
PhoenixBio USA Corp. Miscellaneous Commercial ServicesCommercial Services Part of PhoenixBio Co., Ltd., PhoenixBio USA Corp. develops technologies for mass propagation of human cells into laboratory animals. The company is based in New York, NY. Yoshio Morikawa has been the CEO of the company since 2015. | Commercial Services |
KMT Hepatech, Inc.
KMT Hepatech, Inc. Miscellaneous Commercial ServicesCommercial Services KMT Hepatech, Inc. provides vivo research services focusing on preclinical development of Hepatitis C, Hepatitis B, and Malaria therapeutics and vaccines. It offers scientific evaluation services for drug metabolism, lipoprotein metabolism, dose response, and drug treatment. The firm provides KMT Mouse, a transgenic mouse model for practical testing of HCV drug candidates. The company was founded by Norman Miles Kneteman, David F. Mercer and David Lorne John Tyrrell in 2001 and is headquartered in Edmonton, Canada. | Commercial Services |
- Bolsa de valores
- Insiders
- Takashi Shimada
- Experiencia